



Human NGAL/MMP-9 complex ELISA kit

| Product Code | CSB-EQ01026975HU |
|---------------------------------|--|
| Abbreviation | NGAL/MMP-9 complex |
| Protein Biological Process 1 | Tumor marker |
| Target Name | NGAL/MMP-9 complex |
| Product Type | ELISA Kit |
| Immunogen Species | Homo sapiens (Human) |
| Sample Types | serum, plasma, saliva, cell culture supernates, tissue homogenates |
| Detection Range | 0.313 ng/mL-20 ng/mL |
| Sensitivity | 0.029 ng/mL |
| Assay Time | 1-5h |
| Sample Volume | 50-100ul |
| Detection Wavelength | 450 nm |
| Lead Time | 3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx. |
| Research Area | Metabolism |
| Description | The house NOAL/MAD O complete FLICA Little controlle for some of the time. |

The human NGAL/MMP-9 complex ELISA kit is suitable for quantitatively determining human NGAL/MMP-9 complex in multiple samples, including serum, plasma, saliva, cell culture supernates, or tissue homogenates. This assay employs the bi-antibody sandwich technique and enzyme-substrate chromogenic reaction to quantify human NGAL/MMP-9 complex levels in the sample. The amount of synthesized colored product is positively related to the analyte of interest in the sample.

NGAL protects MMP-9 from proteolytic degradation and enhances its stability and enzymatic activities by binding and forming the NGAL/MMP-9 complex. The NGAL/MMP-9 complex is involved in the development and progression of cancer. NGAL/MMP-9 complex expression and activities have been detected in tissue and urine samples from patients with vascular anomalies and cancers. NGAL, MMP-9, and their complex NGAL/MMP-9 have been proposed as soluble biomarkers for numerous malignancies.

Product Precision

Intra-assay Precision (Precision within an assay): CV%<8%

Three samples of known concentration were tested twenty times on one plate to assess.

Inter-assay Precision (Precision between assays): CV%<10%

Three samples of known concentration were tested in twenty assays to assess.





Linearity

To assess the linearity of the assay, samples were spiked with high concentrations of human NGAL/MMP-9 complex in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.

| | Sample | Serum(n=4) |
|------|-----------|------------|
| 1:10 | Average % | 91 |
| | Range % | 87-98 |
| 1:20 | Average % | 95 |
| | Range % | 90-102 |
| 1:40 | Average % | 93 |
| | Range % | 87-99 |
| 1:80 | Average % | 94 |
| | Range % | 86-105 |
| | | |


Recovery

The recovery of human NGAL/MMP-9 complex spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.

| Sample Type | Average % Recovery | Range |
|-------------------|--------------------|--------|
| Serum (n=5) | 99 | 94-103 |
| EDTA plasma (n=4) | 94 | 87-100 |

Typical

These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.



ng/ml OD1 OD2 Average Corrected

| - | | | - | | |
|-------|---------|-------|-------|-------|--|
| 20 | 1.955 2 | 2.004 | 1.980 | 1.857 | |
| 10 | 1.637 1 | .629 | 1.633 | 1.510 | |
| 5 | 1.204 1 | .217 | 1.211 | 1.088 | |
| 2.5 | 0.8940 | .907 | 0.901 | 0.778 | |
| 1.25 | 0.573 0 |).582 | 0.578 | 0.455 | |
| 0.625 | 0.4160 |).424 | 0.420 | 0.297 | |
| 0.313 | 0.2810 |).270 | 0.276 | 0.153 | |
| 0 | 0.1240 |).121 | 0.123 | | |

Msds

{"0":{"fileurl":"https://www.cusabio.com/uploadfile/msds/MSDS CSB-EQ01026975HU.pdf","filename":"MSDS"}}